Edition:
United Kingdom

ANI Pharmaceuticals Inc (ANIP.OQ)

ANIP.OQ on NASDAQ Stock Exchange Global Market

59.97USD
20 Apr 2018
Change (% chg)

$-0.67 (-1.10%)
Prev Close
$60.64
Open
$60.23
Day's High
$60.23
Day's Low
$59.32
Volume
18,790
Avg. Vol
47,404
52-wk High
$74.63
52-wk Low
$42.26

Chart for

About

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.... (more)

Overall

Beta: 2.84
Market Cap(Mil.): $624.28
Shares Outstanding(Mil.): 11.64
Dividend: --
Yield (%): --

Financials

  ANIP.OQ Industry Sector
P/E (TTM): 119.03 84.02 32.74
EPS (TTM): 0.45 -- --
ROI: 1.72 1.58 14.38
ROE: 3.09 2.41 16.07

BRIEF-ANI Pharmaceuticals Announces Approval Of Morphine Sulfate Oral Solution

* ANI PHARMACEUTICALS ANNOUNCES APPROVAL OF MORPHINE SULFATE ORAL SOLUTION

18 Apr 2018

BRIEF-ANI Acquires 23 ANDAs From IDT Australia

April 4 ANI Pharmaceuticals Inc - Deal For $2.6 Mln And A Limited Single :

04 Apr 2018

BRIEF-IDT Australia To Divest Selection Of Generic Product Portfolio To Ani Pharmaceuticals

* TO DIVEST A SELECTION OF ITS GENERIC PRODUCT PORTFOLIO TO ANI PHARMACEUTICALS INC

04 Apr 2018

BRIEF-ANI Pharmaceuticals Q4 Adjusted Non-GAAP Earnings Per Share $1.08

* ANI PHARMACEUTICALS REPORTS RECORD FULL YEAR RESULTS, REPORTS FOURTH QUARTER 2017 RESULTS, AND PROVIDES 2018 GUIDANCE

27 Feb 2018

BRIEF-Ani Pharmaceuticals Enters Five-Year $125 Mln Senior Secured Credit Facility With Citizens Bank

* ANI PHARMACEUTICALS ENTERS FIVE-YEAR $125 MILLION SENIOR SECURED CREDIT FACILITY WITH CITIZENS BANK

29 Dec 2017

BRIEF-Ani Pharmaceuticals Acquires Four NDAs From AstraZeneca For $46.5 Mln

* ANI PHARMACEUTICALS ACQUIRES FOUR NDAS FROM ASTRAZENECA FOR $46.5 MILLION

29 Dec 2017

BRIEF-ANI Pharmaceuticals Q3 gaap earnings per share $0.40

* ANI Pharmaceuticals reports record third quarter and year-to-date 2017 results and narrows full year guidance

02 Nov 2017

Earnings vs. Estimates